Compare Sanofi SA (SNY) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.5 (market cap $7.36B). The key difference: Sanofi SA is far larger — about 12.9× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Sanofi SA pays a 6.01% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| SNY | SPXL | |
|---|---|---|
Market Cap | $95.18B | $7.36B |
Volume | 2,995,646 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $301.38 |
52-Week Low | $39.51 | $170.20 |
Typical Hold Time | 94 Days | 32 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
SPXL trades at $298.10, up 0.42% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 66.91 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation concerns despite strong earnings growth projections of 35% for 2026. The index faces concentration risks with top holdings accounting for 40% of value.
Outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though profit growth is expected to slow to 15% in 2027. Key risks include market concentration, geopolitical uncertainty, and potential Fed policy impacts. Technical support at $289 and resistance at $300 will be critical near-term levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
